<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639600</url>
  </required_header>
  <id_info>
    <org_study_id>95/CHUG/10/C2</org_study_id>
    <nct_id>NCT00639600</nct_id>
  </id_info>
  <brief_title>Transplantation of Pancreatic Islets in Patients With Type 1 Diabetes Mellitus and Functional Kidney Graft</brief_title>
  <acronym>GRAGIL1</acronym>
  <official_title>Transplantation d'îlots pancréatiques allogéniques Adultes Pour le Traitement du diabète insulinodépendant. Etude GRAGIL 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research project is supported by a multicentric network of collaborators whose goal is&#xD;
      to assess the efficacy of transplanting allogenic pancreas islets to restore insulin&#xD;
      secretion in patients with type 1, insulin-dependent diabetes mellitus with kidney&#xD;
      transplantation and to improve their metabolic control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to demonstrate the beneficial effect of islet allotransplantation in&#xD;
      patients with type 1 diabetes with no endogenous insulin secretion, and with a functional&#xD;
      kidney graft. The other objectives are to evaluate the conditions for the efficacy of islet&#xD;
      cell transplantation, to assess the improvement in quality of life and the cost of the islet&#xD;
      cell transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    a new study has began recently&#xD;
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of insulin-independence at 6 and 12 months after transplantation, duration of insulin-independence, survival curves</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance (Measurement of portal pressure during islet injection) Quality of life (Questionnaires SF-36 and DQOL at inclusion time, then every 6 months during their waiting period and then 6 months and 12 months after transplantation) Costs</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>human pancreatic islet transplantation</intervention_name>
    <description>human pancreatic islet transplantation</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes mellitus&#xD;
&#xD;
          -  Disease duration &gt; 5 years&#xD;
&#xD;
          -  ketose antecedents&#xD;
&#xD;
          -  Basal and stimulated plasma C-&lt; 0.2 ng/ml,&lt;0.06 nmol/l (glycemia must be measured&#xD;
             simultaneously_ 1.20 g/l or 6.6 mM, stimulation with glucagon IV 1 mg -Measured at à&#xD;
             T0 and T 6 min)&#xD;
&#xD;
          -  Established kidney graft ≥ 6 months&#xD;
&#xD;
          -  Current creatinine clearance: ≥ 50 ml/min/1.73 m² and Proteinuria &lt; 0.5 g/24h&#xD;
&#xD;
          -  HbA1C&lt; 12%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemostasis problems&#xD;
&#xD;
          -  Documented hepatic pathology&#xD;
&#xD;
          -  Patient under 18 or over 65 year-old&#xD;
&#xD;
          -  Women with body weight over 70 kg (tolerance of 2 kg between inclusion day and&#xD;
             transplantation day) or BMI &gt; 26&#xD;
&#xD;
          -  Men with body weight &gt; 75 kg (tolerance of 3 kg between inclusion day and&#xD;
             transplantation day) or BMI &gt; 26&#xD;
&#xD;
          -  insuline needs &gt; 0.7 U/kg/j or 50 U/j&#xD;
&#xD;
          -  Serious life-threatening pathology&#xD;
&#xD;
          -  untreated hyperlipidemia&#xD;
&#xD;
          -  Hypersensitivity to drugs rapamycine-alike&#xD;
&#xD;
          -  Liver disease (transaminases or total bilirubin ≥ 3N)&#xD;
&#xD;
          -  Failure to communicate or cooperate with the investigator&#xD;
&#xD;
        Exclusion criteria that are specific to the use of Rapamycine&#xD;
&#xD;
          -  Hypercholesterolemia (&gt; 350mg/dl, 9,1 mmol/l) not controlled&#xD;
&#xD;
          -  Hypertriglyceridemia (&gt; 500 mg/dl, 5,6 mmol/l) not controlled&#xD;
&#xD;
          -  Leukocytes &gt; 4500 /mm3 , neutrophils &gt; 2000/ mm3, platelets &gt; 100000/ mm3&#xD;
&#xD;
          -  Any clinical or biological pathology that could interfere with the study&#xD;
&#xD;
          -  Past or present neoplasia (with the exception of non melanoma skin cancers)&#xD;
&#xD;
          -  Any hemostasis disorder needing a prolonged treatment with anticoagulation drugs.&#xD;
             Low-dose aspirin is permitted.&#xD;
&#xD;
          -  Pregnancy, lactation, pregnancy project or absence of efficient contraception&#xD;
&#xD;
          -  Any medical or psychosocial condition susceptible to interfere with the study, such as&#xD;
             drug abuse or recent alcohol abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Y Benhamou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Grenoble, Department of Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Endocrinology</name>
      <address>
        <city>Strasbourg</city>
        <zip>66000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Department of Surgery</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>March 14, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>May 28, 2010</last_update_submitted>
  <last_update_submitted_qc>May 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pierre-Yves Benhamou</name_title>
    <organization>University Hospital, Grenoble</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

